



CORRECTION

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Marilyn K. Glassberg · Steven D. Nathan · Chin-Yu Lin ·
Elizabeth A. Morgenthien · John L. Stauffer · Willis Chou ·
Paul W. Noble

Published online: September 9, 2019
© The Author(s) 2019

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-019-01052-y>

In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given below

The original article can be found online at <https://doi.org/10.1007/s12325-019-01052-y>.


M. K. Glassberg (✉)
University of Miami Health System, Miami, FL, USA
e-mail: MGlassbe@med.miami.edu

S. D. Nathan
Inova Fairfax Hospital, Falls Church, VA, USA

C.-Y. Lin · E. A. Morgenthien · J. L. Stauffer
Genentech, Inc., South San Francisco, CA, USA


W. Chou
FibroGen, San Francisco, CA, USA

P. W. Noble
Cedars-Sinai Medical Center, Los Angeles, CA, USA



No. at Risk

Pirfenidone	623	607	579	546	532	293	162	87	20	2
Placebo	624	611	591	563	540	293	138	77	22	3



No. at Risk

Pirfenidone	623	607	572	536	520	283	157	84	20	2
Placebo	624	602	581	553	530	288	140	79	22	3

Fig. 2 Time to first major adverse cardiac event–plus (a) and time to first bleeding event (b)

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction

in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.